What is the role of simvastatin in the pathophysiology of factor XIII (FXIII) deficiency?

Updated: Aug 01, 2019
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Perumal Thiagarajan, MD  more...
  • Print

Simvastatin is a commonly used cholesterol-lowering agent. A non–antibody-mediated drug-induced reduction in FXIII activity as part of a broader reduction in hemostatic activation has been suggested to be the reason for the proven antithrombotic efficacy of simvastatin in clinical trials. [55] Blood samples were obtained sequentially every 30 seconds from a bleeding time cut in patients with coronary artery disease, before and 3 months after simvastatin treatment. Samples were analyzed for the time-course drop in fibrinogen levels and activation of factors II, V, and XIII by quantitative Western blot analyses. Simvastatin, independent of its effects on cholesterol, significantly reduced the rate of blood clotting, as evidenced by reduced formation of several activation products including FXIIIa.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!